![PDF] Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. | Semantic Scholar PDF] Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/04a3d4ce989f432a02924f0cc761c89871af398d/4-Table2-1.png)
PDF] Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. | Semantic Scholar
![Optimizing carboplatin dosing by an improved prediction of carboplatin clearance using a CT‐enhanced estimate of renal function - Molenaar‐Kuijsten - 2023 - British Journal of Clinical Pharmacology - Wiley Online Library Optimizing carboplatin dosing by an improved prediction of carboplatin clearance using a CT‐enhanced estimate of renal function - Molenaar‐Kuijsten - 2023 - British Journal of Clinical Pharmacology - Wiley Online Library](https://bpspubs.onlinelibrary.wiley.com/cms/asset/4d082790-9813-426a-a69f-b4448ee5c584/bcp15789-fig-0004-m.jpg)
Optimizing carboplatin dosing by an improved prediction of carboplatin clearance using a CT‐enhanced estimate of renal function - Molenaar‐Kuijsten - 2023 - British Journal of Clinical Pharmacology - Wiley Online Library
![Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance - ScienceDirect Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419640986-gr1.jpg)
Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance - ScienceDirect
![Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP) | Breast Cancer Research and Treatment Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP) | Breast Cancer Research and Treatment](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs10549-020-05868-z/MediaObjects/10549_2020_5868_Fig1_HTML.png)
Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP) | Breast Cancer Research and Treatment
![Overestimation of carboplatin doses is avoided by radionuclide GFR measurement | British Journal of Cancer Overestimation of carboplatin doses is avoided by radionuclide GFR measurement | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2012.393/MediaObjects/41416_2012_Article_BFbjc2012393_Fig1_HTML.jpg)